NCT07046182View on ClinicalTrials.gov

Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 21, 2023

Primary Completion Date

May 26, 2028

Study Completion Date

May 26, 2028

Conditions
Angioimmunoblastic T-cell Lymphoma (AITL)
Interventions
BIOLOGICAL

CEP + Dasatinib + Azacitidine

CEP + Dasatinib + Azacitidine as the first-line treatment regimen for patients with Angioimmunoblastic T-cell Lymphoma

Trial Locations (1)

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Zhengzhou University

OTHER